Company profilePharmaceutical#892 of 1,318 in Pakistan✓ No DRAP alerts

CELLGENE PHARMACEUTICALS INTERNATIONAL

Pharmaceutical company · 6 brands · 7 molecules

Ranked #6 of 15 companies in Other Nervous System Drugs

6 registered products 8 pharmaceutical brands 7 distinct molecules 0 DRAP alerts

Company overview

6
registered products
8
pharmaceutical brands
7
distinct molecules
5
therapeutic classes
0
DRAP alerts

CELLGENE PHARMACEUTICALS INTERNATIONAL is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 6 product registrations across 7 distinct molecules. Its portfolio is concentrated in Other Nervous System Drugs and Neuro. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by CELLGENE

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antiepileptics 1

Top molecules by brand count

Memantine2 brands
Topiramate1 brand
Quetiapine1 brand
Quetiapine ...... 100 Mg1 brand
Quetiapine ...... 25 Mg1 brand
Duloxetine1 brand

Therapeutic classes

Other Nervous System Drugs · 2Neuro · 2Antidepressants · 2Antiepileptics · 1Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 1

Conditions treated

Alzheimer`S · 1Schizophrenia/Psychosis · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official2 products · Rs 704.74 – Rs 2,537.05
DVAGO1 products · Rs 292.9 – Rs 292.9
Servaid2 products · Rs 875.1 – Rs 1,400.1
Median across source: Rs 1,137.6

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NABIQASIM INDUSTRIES (PVT) LTD. holds 195 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir
GETZ PHARMA PAKISTAN (PVT) LTD. holds 274 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
PharmEvo Private Limited holds 120 molecules not in this portfolio
AgomelatineAlcoholAmlodipineAnastrazoleApixabanAprepitant

Get the full profile for CELLGENE

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.